Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

The Methodist Hospital

Neither a doctor nor a teaching hospital

Research payments

$728,588

93 payments

Through program year 2025, The Methodist Hospital is reported as receiving $728,588 in research payments, across 93 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $38,935 5
2024 Research $32,819 6
2023 Research $231,149 6
2022 Research $35,378 7
2021 Research $45,473 11
2020 Research $301,467 29
2019 Research $43,366 29

Breakdown

Who paid Research payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $225,156 5 payments
  2. Guerbet LLC $84,512 2 payments
  3. Boston Scientific Corporation $70,920 9 payments
  4. Ge Healthcare $51,146 4 payments
  5. Agios Pharmaceuticals, Inc. $46,423 5 payments
  6. GlaxoSmithKline, LLC. $41,692 10 payments
  7. Lexicon Pharmaceuticals, Inc. $32,100 1 payment
  8. Argenx US, Inc. $31,850 3 payments
  9. Penumbra, Inc. $31,250 19 payments
  10. AstraZeneca UK Limited $30,300 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. MULTICENTER PHASE I/Ib TRIAL OF OLAPARIB IN COMBINATION WITH VORINOSTAT IN PATIENTS WITH RELAPSED/REFRACTORY AND/OR METASTATIC BREAST CANCER $181,836 1 payment
  2. Reprise III $70,920 9 payments
  3. Effect of MitraClip on Acute and Chronic Reverse C $56,469 1 payment
  4. A Phase 3| Open Label| Multicenter Study of Flurpiridaz (18F) Injection for Positive Emission Tomography (PET) Imaging $49,412 3 payments
  5. A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) $43,320 4 payments
  6. A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Gr $39,904 8 payments
  7. Lx1606.1-207-Btc $32,100 1 payment
  8. A randomized, double-blinded, placebo-controlled, phase 3, parallel-group design study evaluating the efficacy and safety of efgartigimod PH20 SC administered by prefilled syringe in adult participants with ocular myasthenia gravis $31,850 3 payments
  9. A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination with New Hormonal Agents in Patients with Metastatic Prostate Cancer (PETRANHA) $30,300 1 payment
  10. Complete $29,375 14 payments
What the money was spent on Research payments · program years 2019–2025
  1. Patient care $26,620 16 payments
  2. Other $5,800 4 payments
  3. Professional salary support $5,000 1 payment
  4. Overhead $500 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record